Bangkok Genomics Innovation PCL (BKGI)

Currency in THB
1.52
+0.02(+1.33%)
Closed·

BKGI Financial Summary

Key Ratios

P/E Ratio18.02
Price/Book1.61
Debt / Equity4.2%
Return on Equity9.31%
Dividend Yield3.29%
EBITDA64.83M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2022
31/12
2023
31/12
2024
31/12
* In Millions of THB (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.08%
Dividend Yield
3.29%
Industry Median 3.42%
Annualised payout
0.05
Paid annually
5-Years Growth
-
Growth Streak

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 2.20
(+44.74% Upside)

Earnings

Latest Release
May 15, 2025
EPS / Forecast
0.01 / --
Revenue / Forecast
79.00M / --
EPS Revisions
Last 90 days

FAQ

What were Bangkok Genomics Innovation PCL's earnings for the latest quarter?

The Bangkok Genomics Innovation PCL EPS (TTM) is 0.08. Bangkok Genomics Innovation PCL reported sales of 78.54, net income of 8.12, and EPS of 0.01 for the latest quarter.

What was Bangkok Genomics Innovation PCL's net income for the latest quarter?

Bangkok Genomics Innovation PCL's net income for the latest quarter was 8.12.

How did Bangkok Genomics Innovation PCL's performance compare year-over-year in the latest quarter?

The company's revenue moved from 95.77 in the previous quarter to 78.54 in the latest quarter, and net income moved from 12.31 to 8.12 compared to the previous quarter.

What is Bangkok Genomics Innovation PCL's net profit margin on a TTM basis?

Bangkok Genomics Innovation PCL's trailing twelve months (TTM) net profit margin is 14.86%.

How does Bangkok Genomics Innovation PCL's debt to equity ratio compare to industry standards?

Bangkok Genomics Innovation PCL's total debt-to-equity ratio is 4.20%.

What is Bangkok Genomics Innovation PCL's return on investment on a TTM basis?

Bangkok Genomics Innovation PCL's trailing twelve months (TTM) return on investment (ROI) is 9.31%.

Did Bangkok Genomics Innovation PCL gain or lose cash last quarter?

In the latest quarter, Bangkok Genomics Innovation PCL's net change in cash was 40.80 million.

What were Bangkok Genomics Innovation PCL's total assets and liabilities in the latest quarter?

As of the latest quarter, Bangkok Genomics Innovation PCL reported total assets of 614.75 million and total liabilities of 45.61 million.

How has Bangkok Genomics Innovation PCL's total revenue grown this year?

Bangkok Genomics Innovation PCL's total revenue was 95.77 in the previous quarter and 78.54 in the latest quarter.

What is Bangkok Genomics Innovation PCL's gross margin on a TTM basis?

Bangkok Genomics Innovation PCL's trailing twelve months (TTM) gross margin is 40.99%.

What was Bangkok Genomics Innovation PCL's revenue per share for the latest quarter?

Bangkok Genomics Innovation PCL's revenue per share for the latest quarter was 0.58.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.